Exagen’s autoimmune bet: Can a fast‑growing niche diagnostics player turn scale into durability?

On 11 May 2026, Exagen Inc. opened its Q1 earnings call with a familiar mix of progress and pressure. “We’re starting 2026 off well,” President and CEO John Aballi told investors, citing record first quarter revenue of $17.3 million, up 12% year over year. In the same breath, he reminded listeners that this growth is playing out inside an autoimmune testing market that Exagen pegs at over $2.2 billion, growing about 5% annually, where the company believes it holds just over 3% share. The opportunity set is large; the company’s current footprint is still small.

To understand what Exagen is trying to build, it helps to start with the diseases it serves. Autoimmune and autoimmune‑related conditions, from systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) to antiphospholipid syndrome (APS) and various connective tissue diseases, arise when the immune system mistakenly attacks healthy tissues. Clinically, they are notorious for being difficult to diagnose. Symptoms such as fatigue, joint pain, rashes and vague inflammatory markers can mimic other illnesses for years. Many patients cycle through multiple specialists and inconclusive lab panels before landing on a firm diagnosis.

The stakes for getting these diagnoses right and early are high. Delayed identification of lupus, for example, can mean irreversible kidney damage or central nervous system involvement before disease‑modifying treatment begins. Similarly, untreated RA can lead to joint erosion and disability, even though outcomes improve markedly when therapy starts within months of symptom onset. For physicians, the challenge is separating true autoimmune disease from mimics using clinical judgment and a patchwork of legacy laboratory tests that are often insensitive, nonspecific or poorly integrated into clear decision pathways.

Exagen’s answer is AVISE, a branded portfolio of blood‑based autoimmune diagnostics that combines conventional biomarkers with newer, sometimes proprietary, signals into composite scores. The flagship product, AVISE CTD, is designed as a broad connective tissue disease panel. It aims to help rheumatologists distinguish between conditions like lupus, Sjögren’s syndrome, and undifferentiated connective tissue disease, and to rule out autoimmune disease when symptoms are ambiguous. The test integrates traditional autoantibodies, such as anti‑double‑stranded DNA or extractable nuclear antigens, with cell‑bound complement activation products that capture immune activity more dynamically than standard complement levels.

Around CTD, Exagen has built a series of more targeted assays: AVISE Lupus to refine SLE diagnosis, AVISE APS for antiphospholipid syndrome, SLE Prognostic to stratify risk of organ involvement, AVISE Vasculitis AAV for ANCA‑associated vasculitis, as well as tests that track disease activity and treatment safety such as AVISE PC4d, SLE Monitor, and drug monitoring panels for methotrexate (MTX) and hydroxychloroquine (HCQ). In rheumatoid arthritis, Exagen offers markers including Anti‑CarP and, more recently, anti‑PAD4, aiming to capture seronegative or early disease that falls through the cracks of classic rheumatoid factor and anti‑CCP testing.

The commercial thesis is that rheumatologists and related specialists will adopt AVISE tests if they consistently reduce diagnostic uncertainty and fit into existing clinic workflows. That adoption appears to be broadening. In Q1 2026, Aballi reported that AVISE CTD test volume grew 10% year over year, roughly double the company’s estimated 5% growth rate for the overall autoimmune testing market, a signal that Exagen is gaining share within its niche. Ordering clinicians were up 15% year over year, suggesting not just heavier use by existing customers but real expansion of the prescriber base.

Pricing is moving in Exagen’s favor as well. The company’s preferred profitability lens is trailing 12‑month average selling price (ASP) for AVISE CTD, which smooths quarter‑to‑quarter billing noise and revenue adjustments. By Q1 2026, that ASP reached $444, up 6% from roughly $419 a year earlier and marking the 12th consecutive quarter of trailing 12‑month ASP increases. That pricing power, layered on volume growth exceeding market expansion, is what underpins the argument that Exagen can build a durable autoimmune diagnostics franchise rather than a transient single‑product spike.

Exagen’s push into this autoimmune niche has taken more than two decades to cohere. The company traces its roots to 2002, when it was incorporated as Exagen Diagnostics, Inc., a small lab‑based startup focused on developing diagnostic tests. In the early years, it operated largely under the radar, refining assay technology and navigating the complex regulatory environment that governs laboratory‑developed tests in the United States. Autoimmune disease was always a focus, but the portfolio was less defined and the commercial engine still nascent.

By the late 2010s, management had sharpened the story. In January 2019, the business formally changed its name to Exagen Inc., a subtle but telling shift that signaled ambitions beyond a niche diagnostics lab. Later that year, on 19 September 2019, Exagen completed its initial public offering and listed on the NASDAQ Global Market under the ticker XGN. The IPO brought new capital and scrutiny, along with pressure to turn a promising autoimmune testing suite into a scaled, repeatable revenue model.

Exagen’s 2020 and 2023 annual reports mark the period in which the company matured as a public, autoimmune‑focused diagnostics company. Those filings chronicled a transition from a broader specialty lab to a more tightly defined AVISE‑centric platform aimed primarily at rheumatology and related specialties. Over that stretch, the company leaned into its strengths: composite biomarkers that combine complement activation products with standard autoantibodies, and a commercial footprint focused on community‑based clinicians rather than large academic centers alone.

That repositioning has effectively made AVISE and autoimmune disease the company’s defining bet. Instead of pursuing a sprawling menu of specialty lab assays, Exagen is concentrating on a handful of high‑burden, high‑uncertainty conditions where differentiated diagnostics can meaningfully influence treatment. Lupus, RA, vasculitis, antiphospholipid syndrome and emerging areas such as myositis now sit at the center of the strategy. Success, in this framing, depends less on technological novelty for its own sake and more on whether AVISE panels become embedded in everyday rheumatology practice.

Leadership is central to that narrative. Aballi, who serves as President and Chief Executive Officer, is the main architect and public face of Exagen’s growth plan. On earnings calls, he frames the company’s mission as building “a durable company that compounds value over time” by focusing on three core objectives: expanding adoption of its products, increasing ASP through disciplined revenue cycle execution, and delivering a steady cadence of innovation that meets unmet clinician needs. That trilogy has become the company’s strategic mantra.

Alongside Aballi is Chief Financial Officer Jeffrey Black, who joined with a mandate to tighten the financial story and guide Exagen along a path toward profitability. Black’s commentary tends to be grounded in margin trajectories, cash flow timing and the operational levers behind ASP and volume. When he emphasizes that gross margin can progress to the mid‑60s over time, the claim is rooted in incremental improvements in reimbursement, lab productivity and overhead absorption rather than dramatic structural change.

Around them, investor‑facing executives help translate the technical details of autoimmune diagnostics into a capital markets narrative. Vice President of Investor Relations Tina Jacobsen hosts the Q1 2026 earnings call, setting up the discussion for Aballi and Black and fielding questions from analysts. On the Q3 2025 call, Ryan Douglas, in a corporate communications role, handled the standard forward‑looking statements disclaimer and introduced management, underscoring how Exagen has professionalized its communication as it has grown. This supporting cast may be less visible than the CEO and CFO, but they are part of the infrastructure required to sustain public company life.

The evolution from a 2002 startup to a 2019 IPO and, by 2025 and 2026, a focused AVISE autoimmune diagnostics player is not simply chronological. It is also strategic: a narrowing of scope, a deeper investment in a single category and a more explicit articulation of how Exagen plans to earn its way to durable profitability. That clarity sets the stage for evaluating whether the current growth metrics are sufficient to support the ambition.

Exagen’s recent financial performance suggests a business that is learning how to scale. Between 2024 and late 2025, the company moved from modest revenue growth to what Aballi has described as the strongest stretch in Exagen’s history. By Q3 2025, year‑to‑date revenue had grown 19% compared with the same period in 2024, driven by an 8% increase in testing volume and a 9% increase in ASP. For a diagnostics company still in the early innings of market penetration, that balanced growth profile matters: it signals both increased clinical usage and improved monetization.

Q3 2025 stands out as an inflection point. “I’m pleased to report that Q3 was the strongest quarter in Exagen’s history,” Aballi told investors on the November call, citing robust volume growth and continued execution across commercial, scientific and operational teams. Black underscored the step change, noting that fourth quarter revenue of $17.2 million was the highest in the company’s history at the time, representing nearly 40% growth over Q3 2024. Even adjusting for more than $1 million of downside revenue adjustments in the prior‑year period, management framed the expansion as meaningfully ahead of the underlying market.

Looking across the first three quarters of 2025, Exagen generated roughly $50 million in revenue, according to Black, with trailing 12‑month ASP up over 9% and volume up over 8%. That kind of mid‑teens blended pricing and volume expansion is not sustainable indefinitely in a mature diagnostics segment, but Exagen’s claim is that at just over 3% share of what it sees as a $2.2 billion market, the company has room to compound at above‑market rates for some time.

The strategy behind those numbers is straightforward. Aballi frames it as a three‑part plan: expand adoption, increase ASP through disciplined revenue cycle management, and maintain a steady cadence of innovation. Black reinforced the idea that both levers must move together to support the model when he said on the Q1 2026 call that “once again, we achieved record top line performance by growth in both testing volume and ASP.”

On the volume side, Exagen reported that AVISE CTD test volume increased 10% year over year in Q1 2026, double the estimated 5% market growth rate, implying that the company is taking share within autoimmune diagnostics rather than simply riding category expansion. The 15% year‑over‑year increase in ordering clinicians adds another layer of validation; growth is not confined to a handful of high‑volume prescribers but is broadening across the customer base.

On pricing, the company has now racked up 12 consecutive quarters of trailing 12‑month ASP increases for AVISE CTD. ASP reached $441 by Q3 2025, representing a 9% year‑over‑year increase, and then rose to $444 by Q1 2026, another 6% rise from the prior year. These gains reflect a mix of better payer contracting, improved documentation and appeals processes, and disciplined follow‑through on collections rather than simple list price hikes. In a segment where reimbursement risk can quickly erode margins, Exagen’s ability to steadily nudge realized pricing higher has become a core pillar of the bull case.

Commercial expansion has underpinned these trends. By Q3 2025, Exagen operated with 45 sales territories, up from 42 at the end of Q3 2024, indicating measured but real investment in field coverage. Aballi highlighted that Q3 volume was the highest the company had ever recorded for a third quarter and that Exagen did not see the typical seasonal slowdown, suggesting the sales force is driving more consistent ordering patterns. For a specialty diagnostics company, aligning territory expansion and representative productivity with revenue growth is a critical operational test.

The momentum carried into early 2026. Q1 2026 revenue reached $17.306 million, the highest first‑quarter figure in Exagen’s history, up 12% year over year and slightly above the $17.2 million posted in Q3 2025. Management reaffirmed full‑year 2026 revenue guidance of $70 million to $73 million, implying mid‑teens growth at the midpoint from the 2025 revenue range of $65 million to $70 million. If achieved, that trajectory would mark a multi‑year period of double‑digit top‑line expansion.

For all the focus on revenue growth, the central question for Exagen is whether that growth can translate into durable profitability fast enough to justify ongoing investment and cushion the balance sheet. As of Q1 2026, the company remained in the red, but its unit economics were improving.

On the income statement, Q1 2026 gross margin reached 59.0%, relatively unchanged versus Q1 2025 but up 360 basis points sequentially from 55.35% in Q4 2025. That improvement came as ASP continued to rise and as the lab absorbed more fixed costs across a broader revenue base. Black has repeatedly pointed investors toward a long‑term goal of moving gross margins into the mid‑60s, a level that would bring Exagen closer to the economics of more mature diagnostic peers, assuming the company can keep reagent costs, labor and overhead in check while ASPs climb.

Operating leverage is beginning to show, but losses remain meaningful. Q1 2026 operating margin improved to -19.7%, with operating income of -$3.414 million on $17.306 million of revenue, compared with -29.9% in Q4 2025, when operating income was -$4.975 million on $16.631 million of revenue. Net margin followed a similar trajectory, improving from -41.1% in Q3 2025 and -28.1% in Q4 2025 to -22.9% in Q1 2026, or a net loss of $3.967 million. These are still sizable losses, but the direction of travel is toward narrower deficits as volume and ASP gains feed through to the bottom line.

On an adjusted basis, Exagen reported an EBITDA loss of $2.2 million in Q1 2026, excluding depreciation and non‑cash stock‑based compensation. That represented a 14% improvement versus Q1 2025, implying an adjusted EBITDA loss of roughly $2.6 million in the prior‑year period. The adjusted metric is not a substitute for GAAP profitability, but it highlights that the cash‑like component of the loss is shrinking as revenue scales.

Cash flow tells a more volatile story. Free cash flow swung from a positive $2.669 million in Q3 2025 to outflows of $3.094 million in Q2 2025, $3.057 million in Q4 2025, and then a steeper $10.645 million in Q1 2026. Some of that variability reflects timing of collections and working capital movements, especially around year‑end and the start of a new year. But the magnitude of the Q1 2026 outflow underscores that Exagen is still dependent on its cash reserves and that improving adjusted EBITDA does not yet translate into consistent cash generation.

On prior calls, management had suggested that Exagen could achieve cash flow positivity at the high end of its 2025 revenue guidance range of $65 million to $70 million, though Aballi also acknowledged that the timing of sustained cash flow positivity might be pushed into 2026 as the company navigated ASP‑related headwinds. With Q1 2026 free cash flow substantially negative, investors will be watching closely to see whether subsequent quarters show normalization or whether the drag persists.

The balance sheet is, for now, a relative strength. Exagen ended Q1 2026 with just under $22 million in cash, cash equivalents and restricted cash, down from $32.22 million in cash and short‑term investments at year‑end 2025, reflecting the recent cash burn. However, debt fell sharply over the same period, from $27.666 million at Q4 2025 to $4.855 million at Q1 2026, reducing leverage and leaving the company with a net cash position of roughly $16.66 million compared with $4.55 million at year‑end. That deleveraging gives Exagen more flexibility, even as it shortens the absolute cash runway if losses persist.

Liquidity metrics remain healthy but are trending down. The current ratio, a rough gauge of short‑term solvency, slipped from 4.95 at Q2 2025 to 4.08 at Q3 2025 and 3.45 at Q4 2025, before holding roughly steady at 3.47 in Q1 2026. Return on equity has stayed negative, deteriorating to -39.1% at Q3 2025 before improving to -26.8% at Q4 2025 and -27.5% at Q1 2026 as losses narrowed relative to the equity base. The trajectory is in the right direction, but the company still needs to close the gap to break‑even.

In essence, Exagen is trading operating losses and cash burn for growth and capability build‑out. For the strategy to work, a few things must go right. Gross margins need to continue their climb toward the mid‑60s, ASP and volume growth must stay ahead of market averages without provoking payer pushback, and operating expenses must grow slower than revenue. At the same time, the company must manage its innovation pipeline and commercial investments within a finite cash runway, or else tap capital markets again on terms that preserve shareholder value.

Exagen’s growth and margin ambitions rest heavily on its ability to keep innovating within autoimmune diagnostics without overextending its balance sheet. Here, the company is trying to thread a needle: expand its AVISE portfolio with new biomarkers and stand‑alone tests while keeping capital intensity low and generating external validation through clinical research.

Rheumatoid arthritis has been an early proving ground. In 2025, Exagen launched two sets of novel RA biomarkers, culminating in Q3 2025 with the introduction of assays for anti‑PAD4 antibodies. These markers aim to improve sensitivity in detecting RA, particularly in patients who are negative for conventional antibodies. If they perform as advertised, they could help clinicians diagnose RA earlier or in ambiguous cases, potentially expanding the addressable testing population.

Notably, Aballi has emphasized that these RA biomarker efforts have been relatively low cost. He told investors that the projects required less than $3 million in investment and that management expects revenue payback in less than 24 months. For a diagnostics company, that kind of capital efficiency matters: it means that Exagen can refresh and extend its menu without the kind of large, multi‑year R&D bets that characterize drug development, and that new biomarkers can contribute to ASP and volume growth fairly quickly.

The next major product milestone is myositis, a group of rare autoimmune muscle diseases that are often underdiagnosed or misdiagnosed. Aballi has flagged a new stand‑alone myositis diagnostic as Exagen’s first new stand‑alone product since 2020, targeted for commercialization in early 2027. In a field where symptoms such as muscle weakness and fatigue overlap with numerous conditions, and where existing testing algorithms can be fragmented, a well‑validated, comprehensive myositis assay could become a natural extension of the AVISE portfolio in rheumatology and neuromuscular clinics.

Evidence generation is central to these launches. At the American College of Rheumatology (ACR) meeting in Chicago in 2025, Exagen presented six accepted abstracts, including one selected for a plenary talk, highlighting RA biomarkers and broader pipeline work. In early 2026, the company had nine abstracts accepted at Autoimmunity 2026 in Prague, including several tied to myositis research and continued evidence generation across the AVISE portfolio. For payers and clinicians, such conference data and subsequent publications help differentiate AVISE tests from commodity lab panels.

Beyond the core testing business, Exagen is also building a smaller but potentially important Pharma Services segment. This business works with pharmaceutical and biotech companies to provide specialized testing, biomarker analysis and related services that support drug development and clinical trials in autoimmune disease. While still a small contributor to total revenue, its growth trajectory has been steep: from roughly $0.1 million in revenue early in 2024 to about $1.2 million year‑to‑date by Q3 2025, accompanied by a growing backlog.

By Q3 2025, Exagen reported a Pharma Services contract backlog of around $3.5 million to be recognized over the next two to three years. By Q1 2026, that backlog had expanded to over $5 million on the same multi‑year horizon. While backlog is not cash, it offers some visibility into future revenue, and the multi‑year nature of these contracts can smooth out some of the volatility inherent in the testing business. If Pharma Services can scale without consuming disproportionate resources, it could become both a diversification lever and a way to deepen Exagen’s relationships with industry partners.

The strategic logic of these initiatives is twofold. First, new biomarkers and stand‑alone tests such as the RA panels and eventual myositis assay can enrich the AVISE menu, support higher ASPs and create additional reasons for clinicians to stick with Exagen rather than switch to competing labs. Second, Pharma Services can leverage the same scientific and operational infrastructure to tap a different revenue stream with potentially higher margins and longer contracts, provided Exagen avoids overcustomization that erodes scale benefits.

The risks are familiar to anyone who follows diagnostics. New biomarkers must show not only analytical validity but clear clinical utility: they need to change physician behavior in ways that improve patient outcomes or reduce downstream costs. Payers must be persuaded to reimburse them appropriately. And as Exagen pushes into rarer conditions such as myositis, the addressable population shrinks, making commercial execution and evidence even more critical. The company’s decision to keep innovation projects relatively low cost reflects an awareness of those constraints.

Pulling the threads together, Exagen has carved out a small but growing position in autoimmune diagnostics. It is posting double‑digit revenue growth, expanding both test volumes and realized pricing, and gradually improving gross and operating margins. It operates in a market it believes is worth more than $2.2 billion, growing at about 5% annually, where it captures just over 3% share. The remaining question is whether it can convert that foothold into a durable, profitable business before its cash runway narrows too far or larger competitors squeeze its niche.

For investors, several watchpoints stand out over the next two to three years. On the top line, the most immediate indicator will be whether Exagen can sustain double‑digit test volume growth while keeping ASP on its upward trajectory. CTD volume grew 10% year over year in Q1 2026, outpacing the estimated 5% market growth rate, and ordering clinicians increased 15%. Trailing 12‑month AVISE CTD ASP has risen for 12 straight quarters, hitting $444 in Q1 2026. Continued share gains and disciplined revenue cycle management will be essential if those streaks are to continue without provoking pushback from payers or overburdening the sales force.

Margins and cash flow are the second major theme. Gross margin has already climbed from 55.35% in Q4 2025 to 59.0% in Q1 2026, but Exagen’s target band is in the mid‑60s. Progress toward that range, combined with further operating expense discipline, will determine how quickly operating margin can move from -19.7% toward break‑even. At the same time, the company needs to reconcile its improving adjusted EBITDA, which showed a 14% year‑over‑year improvement in Q1 2026 to a $2.2 million loss, with its more volatile free cash flow, which swung to a -$10.645 million outflow in the same quarter after briefly turning positive in Q3 2025.

The balance sheet provides some buffer but not unlimited time. With just under $22 million in cash, cash equivalents and restricted cash at the end of Q1 2026, a net cash position of roughly $16.66 million after debt was reduced to $4.855 million, and a current ratio around 3.5, Exagen is not under immediate liquidity stress. But if free cash flow were to remain deeply negative, the company could eventually need to raise additional capital or slow its investment cadence. The timing and terms of any such capital decisions would likely depend on the trajectory of revenue, margins and the broader financing environment.

Execution on the innovation pipeline will also be a key signal. The RA biomarker suite, including anti‑PAD4, needs to prove that it can drive incremental test adoption and ASP without cannibalizing existing panels or facing significant reimbursement challenges. The planned stand‑alone myositis diagnostic, slated for early 2027, represents a more discrete catalyst: its launch timing, initial uptake and inclusion in clinical guidelines or payer policies will offer a tangible measure of Exagen’s ability to extend AVISE into new disease areas.

Pharma Services will be worth monitoring as a small but potentially strategic contributor. Revenue grew from about $0.1 million early in 2024 to $1.2 million year‑to‑date by Q3 2025, and backlog expanded from around $3.5 million to over $5 million by Q1 2026, to be recognized over the next two to three years. The conversion of that backlog into revenue, and the addition of new contracts, will reveal whether this business can scale in a capital‑efficient way and provide a complementary growth vector to testing.

Ultimately, the Exagen story is a test of whether a focused diagnostics company can build a defensible position in a specific, under‑served niche and then compound that position economically. Aballi’s framing on the Q1 2026 call was that Exagen is “starting 2026 off well,” with record first‑quarter revenue, share gains and improving profitability metrics. The harder, longer‑term question is whether this combination of science, commercial execution and financial discipline will be enough to turn today’s mid‑single‑digit share of a $2.2 billion market into the kind of durable company that compounds value over time, or whether the pressures of reimbursement, competition and capital will catch up first.